【摘要】 罗莫佐单抗是一种具有双重调节作用的人源化单克隆抗体药物，在人体内与硬骨抑素相结合可以明显增加骨量形成，同时减少骨吸收，是一种新型抗骨质疏松药物。国外临床试验中已明确证实其降低骨折风险和增加骨密度的良好作用，但目前国内尚未批准此药物上市。本文从罗莫佐单抗的药物机制、临床疗效、安全性和序贯治疗等方面，综述了国外近年高质量研究，探讨其在治疗骨质疏松症方面的临床应用及最新进展。更多还原

【Abstract】 As a novel kind of anti-osteoporosis medication,romosozumab is a humanized mono-clonal antibody with a dual regulatory function that may considerably boost bone mass production in conjunction with sclerostatin in the human body while lowering bone resorption.Although this drug’s positive effects on lowering fracture risk and improving bone density have been amply demonstrated in foreign clinical trials,it has not been approved by Chinese government for commercialization.In this article,current high-quality international researches on the medication mechanism,clinical efficacy safety,and sequential therapy of romosozumab were reviewed to explore its clinical applicability and the most recent advance in the treatment of osteoporosis.更多还原